¶ BRD2 (Bromodomain-Containing Protein 2)
[^1]
[^2]
[^3]
[^4]
[^5]
[^6]
[^7]
[^8]
| Full Name | Bromodomain-Containing Protein 2 |
| Gene Symbol | BRD2 |
| Aliases | RING3, FSH, NAT |
| Chromosomal Location | 6p21.3 |
| NCBI Gene ID | [6046](https://www.ncbi.nlm.nih.gov/gene/6046) |
| OMIM | [601540](https://omim.org/entry/601540) |
| Ensembl | [ENSG00000204256](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000204256) |
| UniProt | [P25440](https://www.uniprot.org/uniprot/P25440) |
| Protein | Bromodomain-containing protein 2 |
| Associated Diseases | Juvenile myoclonic epilepsy, [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), photosensitive epilepsy |
TNF is a human gene. Variants in TNF have been implicated in Juvenile Myoclonic Epilepsy (JME), Alzheimer's Disease, Parkinson's Disease. This page covers the gene's normal function, disease associations, expression patterns, and key research findings relevant to neurodegeneration.
BRD2 encodes a BET (Bromodomain and Extra-Terminal domain) family transcriptional regulator that reads acetylated histones and recruits transcriptional machinery to active chromatin. BRD2 is located within the major histocompatibility complex (MHC) class II region on chromosome 6p21.3 and plays critical roles in neural development, cell cycle regulation, and inflammatory gene expression.
BRD2 contains:
- Bromodomain 1 (BD1): Preferentially binds di-acetylated H4 (H4K5acK12ac), a mark enriched at gene promoters during active transcription
- Bromodomain 2 (BD2): Binds acetylated H4K5/K8/K12 with broader specificity, contributing to chromatin association during different transcriptional states
- ET domain: Mediates protein-protein interactions with transcription factors, including recruitment of the Mediator complex and transcriptional elongation factors
- SEED domain: BRD2-specific domain that interacts with E2F transcription factors, linking histone acetylation to cell cycle gene expression
BRD2 functions in neural biology through:
- Transcriptional coactivation: BRD2 bridges acetylated chromatin to the transcriptional machinery, facilitating expression of neural-specific genes including ion channels, neurotransmitter receptors, and synaptic proteins
- Cell cycle regulation: BRD2 interacts with E2F1/E2F2 to drive expression of cyclins and CDKs required for neural progenitor proliferation; BRD2 heterozygous knockout mice show reduced neural tube cell proliferation
- GABAergic neuron development: BRD2 is essential for specification and maturation of GABAergic interneurons. BRD2 haploinsufficiency reduces GABAergic neuron density, providing a direct mechanistic link to epilepsy
- Inflammatory regulation: BRD2 co-activates NF-κB-dependent inflammatory gene expression; in microglia, BRD2 occupies promoters of IL-6, TNF, and CCL2
- Chromatin bookmarking: During mitosis, BRD2 remains associated with specific gene promoters, enabling rapid transcriptional reactivation upon mitotic exit — a function critical for maintaining neural progenitor identity
¶ Neural Expression and Brain Distribution
BRD2 is highly expressed throughout the central nervous system:
- Cortex: Enriched in both excitatory and inhibitory neurons across all cortical layers
- Hippocampus: High expression in CA1-CA3 pyramidal cells and GABAergic interneurons
- Thalamus: Strong expression in thalamocortical relay neurons, consistent with roles in epileptogenesis
- Cerebellum: Purkinje cell and granule cell expression
- Developing brain: Critical during embryonic neurogenesis; expression peaks during E11-E15 (mouse) coinciding with interneuron specification and migration
BRD2 is one of the best-characterized genetic risk factors for juvenile myoclonic epilepsy (JME), the most common form of idiopathic generalized epilepsy. The association arises from several lines of evidence:
- Common promoter variants (including rs3918149) that reduce BRD2 expression are significantly enriched in JME patients
- BRD2 heterozygous knockout mice develop spontaneous seizures and photoparoxysmal responses, closely modeling human JME
- BRD2 haploinsufficiency reduces GABAergic interneuron number by 30-50% in cortex and hippocampus, creating an excitatory/inhibitory imbalance that lowers seizure threshold
- The mechanism links to reduced expression of GAD67 (GAD1), the rate-limiting enzyme for GABA synthesis, in BRD2-deficient interneurons
BRD2 contributes to AD pathogenesis through:
- Neuroinflammation: BRD2 co-activates NF-κB-dependent microglial inflammatory programs; BET inhibitors (JQ1, I-BET762) reduce pro-inflammatory cytokine production in AD model microglia
- Tau acetylation: BRD2 interacts with acetyltransferase p300 at the MAPT locus; BRD2-dependent acetylation of tau at K174 and K274 promotes pathological tau aggregation
- Amyloid-beta response: Microglial BRD2 drives expression of inflammatory mediators in response to amyloid-beta oligomers, amplifying the neuroinflammatory cascade
- Microglial activation: BRD2-dependent inflammatory gene expression in microglia contributes to dopaminergic neuron loss in PD models
- Alpha-synuclein: BRD2 occupancy at inflammatory gene promoters is increased by alpha-synuclein fibril stimulation, suggesting a feedforward inflammatory loop
| Variant |
Type |
Population Frequency |
Clinical Significance |
| rs3918149 |
Promoter |
0.25 (European) |
JME susceptibility |
| rs516535 |
Intronic |
0.30 (global) |
Epilepsy risk modifier |
| rs206790 |
Synonymous |
0.18 (global) |
JME association |
| 6p21.3 risk haplotype |
Haplotype |
Variable |
MHC-linked epilepsy risk |
- BET inhibitors: Pan-BET inhibitors (JQ1, I-BET762, OTX-015) and BD2-selective inhibitors (ABBV-744, GSK046) potently suppress neuroinflammation in preclinical AD and PD models. BD2-selective inhibitors may offer better therapeutic windows by preserving BRD2's BD1-mediated housekeeping functions
- Anti-epileptic potential: Understanding BRD2's role in GABAergic specification suggests that enhancing BRD2 expression or function could increase GABAergic tone and raise seizure threshold
- Neuroinflammation targeting: Selectively inhibiting BRD2's inflammatory co-activation function (without blocking its neural developmental role) could reduce chronic neuroinflammation in AD and PD
- Combination strategies: BET inhibitors combined with anti-amyloid or anti-tau therapies may enhance efficacy by simultaneously targeting protein aggregation and the inflammatory response
- BRD4 — BET family, super-enhancer regulation
- EP300 — Histone acetyltransferase, BRD2 partner
- GAD1 — GAD67, GABA synthesis
- NLRP3 — Inflammasome, neuroinflammation
- SMARCA2 — SWI/SNF chromatin remodeler